Last reviewed · How we verify
EGb 761® (Tanakan®)
EGb 761 is a standardized Ginkgo biloba extract that improves blood flow and reduces oxidative stress in the brain and peripheral tissues.
EGb 761 is a standardized Ginkgo biloba extract that improves blood flow and reduces oxidative stress in the brain and peripheral tissues. Used for Age-related cognitive decline and dementia, Peripheral arterial occlusive disease (claudication), Tinnitus and vertigo.
At a glance
| Generic name | EGb 761® (Tanakan®) |
|---|---|
| Sponsor | Ipsen |
| Drug class | Herbal extract / Nootropic |
| Modality | Small molecule |
| Therapeutic area | Neurology / Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
EGb 761 contains flavonoids and terpenoids that enhance microcirculation, increase oxygen and glucose utilization in tissues, and scavenge free radicals. It also modulates neurotransmitter function and reduces platelet aggregation, contributing to improved cognitive and vascular function.
Approved indications
- Age-related cognitive decline and dementia
- Peripheral arterial occlusive disease (claudication)
- Tinnitus and vertigo
Common side effects
- Headache
- Gastrointestinal upset
- Dizziness
- Bleeding risk (minor)
Key clinical trials
- Efficacy and Safety of Ginkgo Biloba Extract EGb761® in Patients With Diabetic Retinopathy (PHASE2)
- Effects of Indena's Virtiva® Plus Ginkgo Biloba Extract on Stress, and Cognitive Performance (NA)
- The Effects of Mirtoselect®, Virtiva®, and Enovita® on Cognitive Performance and Mood States (NA)
- Effect of Aerobic Training and Ginkgo Biloba on Lipids Levels in HIV-positive Patients Undergoing Antiretroviral Treatment (PHASE2, PHASE3)
- Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis (PHASE3)
- "WakeUp" for Vigilance Following Lunch (NA)
- Effect of Audistim® Day/Night on Hearing Comfort and Patient Quality of Life of Patients With Chronic Tinnitus. (NA)
- Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EGb 761® (Tanakan®) CI brief — competitive landscape report
- EGb 761® (Tanakan®) updates RSS · CI watch RSS
- Ipsen portfolio CI